Erratum: Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway (Int J Oncol (2015) 46 (1131-1140) DOI: 10.3892/ijo.2015.2829);Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1131-1140

  Song, Mingzhi ^a   Tian, Xiliang ^a   Lu, Ming ^a   Zhang, Xianbin ^a   Ma, Kai ^a   Lv, Zhichao ^a   Wang, Zhenxing ^a   Hu, Yang ^a   Xun, Chong ^a   Zhang, Zhen ^a   Wang, Shouyu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; Genistein; Osteosarcoma; PPAR ; PTEN

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 5 ETHYNYL 2' DEOXYURIDINE; CHOLECYSTOKININ OCTAPEPTIDE; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEOXYURIDINE DERIVATIVE; GENISTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL COUNTING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MG 63 CELL LINE; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANILIDES; ANTICARCINOGENIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; OSTEOSARCOMA; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 84921924709     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2024.5635     Document Type: Erratum

References (66)

1. Yang Z, Kulkarni K, Zhu W, et al: Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem 10: 1264-1280, 2012.
2. Banerjee S, Li Y, Wang Z, et al: Multi-targeted therapy of cancer by genistein. Cancer Lett 2: 226-242, 2008.
3. Zhang Z, Wang CZ, Du GJ, et al: Genistein induces G2/M cell cycle arrest and apoptosis via atm/p53-dependent pathway in human colon cancer cell. Int J Oncol 1: 289-296, 2013.
4. Ullah MF, Ahmad A, Zubair H, et al: Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol Nutr Food Res 4: 553-559, 2011.
5. Mizushina Y, Shiomi K, Kuriyama I, et al: Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cancer cell proliferation. Int J Oncol 4: 1117-1124, 2013.
6. Hwang KA, Kang NH, Yi BR, et al: Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by 17beta-estradiol or bisphenol A via the inhibition of cell cycle progression. Int J Oncol 2: 733-740, 2013.
7. Xia J, Cheng L, Mei C, et al: Genistein inhibits cell growth and invasion through regulation of mir-27a in pancreatic cancer cells. Curr Pharm Des 33: 5348-5353, 2014.
8. Hilakivi-Clarke L, Onojafe I, Raygada M, et al: Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 11: 1682, 1999.
9. Zhou JR, Mukherjee P, Gugger ET, et al: Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 22: 5231-5238, 1998.
10. Li C, Teng RH, Tsai YC, et al: H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br J Cancer 1: 80-88, 2004.
11. Yang CH, Murti A, Pfeffer SR, et al: Interferon α /β promotes cell survival by activating nuclear factor κB through phosphatidylinositol 3-kinase and Akt. J Biol Chem 17: 13756-13761, 2001.
12. Yamashita K, Suzuki M, Iwata H, et al: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases. FEBS Lett 1: 103-107, 1996.
13. Nikitovic D, Tsatsakis AM, Karamanos NK, et al: The effects of genistein on the synthesis and distribution of glycosaminoglycans/ proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res 23 (1A): 459-464, 2003.
14. Morris C, Thorpe J, Ambrosio L, et al: The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J Nutr 5: 1166-1170, 2006.
15. Zhang B, Shi ZL, Liu B, et al: Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-κB. Anticancer Drugs 3: 288-296, 2010.
16. Liang C, Li H, Shen C, et al: Genistein potentiates the anticancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-kappaB pathway. Anticancer Agents Med Chem 5: 554-563, 2012.
17. Nakamura A, Aizawa J, Sakayama K, et al: Genistein inhibits cell invasion and motility by inducing cell differentiation in murine osteosarcoma cell line LM8. BMC Cell Biol 1: 24, 2012.
18. Rickard DJ, Monroe DG, Ruesink TJ, et al: Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem 3: 633-646, 2003.
19. Salvatori L, Caporuscio F, Coroniti G, et al: Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol 1: 35-44, 2009.
20. Djiogue S, Njamen D, Halabalaki M, et al: Estrogenic properties of naturally occurring prenylated isoflavones in U2OS human osteosarcoma cells: Structure-activity relationships. J Steroid Biochem Mol Biol 4-5: 184-191, 2010.
21. Nakamura H, Wang Y, Kurita T, et al: Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS One 5: e20034, 2011.
22. Dang, ZC, Audinot V, Papapoulos SE, et al: Peroxisome prolifer-ator-activated receptor gamma as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2: 962-967, 2003.
23. Mezei O, Banz WJ, Steger RW, et al: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 5: 1238-1243, 2003.
24. Xiang Q, Lin G, Fu X, et al: The role of peroxisome proliferatoractivated receptor-γ and estrogen receptors in genistein-induced regulation of vascular tone in female rat aortas. Pharmacology 2: 117-124, 2010.
25. Youssef J and Badr M: Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol 1: 68-82, 2011.
26. Willson TM, Lambert MH and Kliewer SA: Peroxisome prolifer-ator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70: 341-367, 2001.
27. Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
28. Bundscherer A, Reichle A, Hafner C, et al: Targeting the tumor stroma with peroxisome proliferator activated receptor agonists. Anticancer Agents Med Chem 7: 816-821, 2009.
29. Rumi MA, Ishihara S, Kazumori H, et al: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 6: 465-477, 2004.
30. Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1: 237-241, 1997.
31. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 15: 3344-3352, 1998.
32. Asou H, Verbeek W, Williamson E, et al: Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 5: 1027-1031, 1999.
33. Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1: 75-80, 1999.
34. Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 15: 8806-8811, 1998.
35. Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 3: 465-470, 1998.
36. Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 4: 1129-1138, 2000.
37. Ali AA, Weinstein RS, Stewart SA, et al: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 3: 1226-1235, 2005.
38. Rzonca SO, Suva LJ, Gaddy D, et al: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 1: 401-406, 2004.
39. Rajkumar T and Yamuna M: Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs 3: 257-265, 2008.
40. Yamaguchi K, Whitlock NC, Liggett JL, et al: Molecular characterisation of canine nonsteroidal anti-inflammatory drugactivated gene. Vet J 1: 89-95, 2008.
41. He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 8: 2235-2245, 2010.
42. Haydon RC, Luu HH and He TC: Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 454: 237-246, 2007.
43. Haydon RC, Zhou L, Feng T, et al: Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 5: 1288-1294, 2002.
44. Yu LX, Yan HX, Liu Q, et al: Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 4: 1322-1333, 2010.
45. Lv L, Xiao XY, Gu ZH, et al: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 1-2: 11-21, 2011.
46. Lu Q, Lu S, Gao X, et al: Norisoboldine, an alkaloid compound isolated from Radix Linderae, inhibits synovial angiogenesis in adjuvant-induced arthritis rats by moderating Notch1 pathwayrelated endothelial tip cell phenotype. Exp Biol Med 8: 919-932, 2012.
47. Seargent JM, Yates EA and Gill JH: GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 8: 933-937, 2004.
48. Patel L, Pass I, Coxon P, et al: Tumor suppressor and antiinflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 10: 764-768, 2001.
49. Wu ZX, Song TB, Li DM, et al: Overexpression of PTEN suppresses growth and induces apoptosis by inhibiting the expression of survivin in bladder cancer cells. Tumour Biol 1: 9-15, 2007.
50. Mikhail M, Velazquez E, Shapiro R, et al: PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 14: 5153-5157, 2005.
51. Raffoul JJ, Wang Y, Kucuk O, et al: Genistein inhibits radiationinduced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107, 2006.
52. Ouyang G, Yao L, Ruan K, et al: Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int 12: 1237-1244, 2009.
53. Wagner ER, He BC, Chen L, et al: Therapeutic implications of PPARgamma in human osteosarcoma. PPAR Res: 956427, 2010.
54. Miao J, Wu S, Peng Z, et al: MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 4: 2093-2098, 2013.
55. Weng L, Brown J and Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 3: 237-242, 2001.
56. Waite KA, Sinden MR and Eng C: Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet 11: 1457-1463, 2005.
57. Choi YH, Lee WH, Park KY, et al: p53-independent induction of p21, reduction of Cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 2: 164-173, 2000.
58. Mayo LD and Donner DB: The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 9: 462-467, 2002.
59. Zhang T, Wang F, Xu H-X, et al: Activation of nuclear factor erythroid 2-related factor 2 and PPARγ plays a role in the genis-tein-mediated attenuation of oxidative stress-induced endothelial cell injury. Br J Nutr 2: 223-235, 2013.
60. Halasova E, Adamkov M, Matakova T, et al: Expression of Ki-67, Bcl-2, survivin and p53 proteins in patients with pulmonary carcinoma. Adv Exp Med Biol 756: 15-21, 2013.
61. Gao Q, Yang S and Kang MQ: Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Rep 6: 1409-1414, 2012.
62. Ma Y and Wang HS: Correlations of Bcl-2 and survivin gene protein expressions in colorectal cancer. Applied Mech Mater 423-426: 362-365, 2013.
63. Kumar P, Miller AI and Polverini PJ: p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 41: 43352-43360, 2004.
64. Fong WH, Tsai HD, Chen YC, et al: Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol 2-3: 180-186, 2010.
65. Ren Y, Sun C, Sun Y, et al: PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 2-3: 169-174, 2009.
66. Kim YJ, Park KJ, Song JK, et al: The PPARgamma agonist protects cardiomyocytes from oxidative stress and apoptosis via thioredoxin overexpression. Biosci Biotechnol Biochem 12: 2181-2187, 2012.